Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
3 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy oral semaglutide 25 mg (64 weeks) and about 1 in 3 taking Wegovy injection 2.4 mg (68 weeks) lost 20% of body weight, alongside diet and exercise
Most providers prefer injectable semaglutide for patients switching from injectable tirzepatide to maintain consistency in delivery method and bioavailability
GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals
Evaluate the Time Commitment GLP-1 agonists: Ongoing use of medication is required for sustained results
US$ 23.91
US$ 23.77
US$ 29.53
US$ 29.53
US$ 24.89
US$ 23.74
US$ 26.22
US$ 20.12
US$ 23.40
US$ 28.05
US$ 23.91
US$ 25.85
